AXOGEN INC (AXGN)
Health Care · medical devices / surgical instruments · NASDAQ
Axogen is a medical technology company dedicated to advancing the field of peripheral nerve repair through its portfolio of nerve allografts, conduits, and wrap technologies.
What AXOGEN INC does
Axogen is a medical technology company focused on the development and commercialization of innovative surgical solutions for peripheral nerve repair. Its portfolio includes processed nerve allografts, nerve conduits, and nerve wrap products used to address nerve damage. The company provides a comprehensive surgical solution to restore nerve function and improve quality of life for patients.
Themes: peripheral nerve repair, regenerative medicine, surgical technologies
Fundamentals
- Price$36.18 as of 2026-10-08 close
- Market cap$1.9B as of 2026-07-27 (share count; price 2026-10-08)
- 1-year return+110.8% 2025-10-08 close $17.16 → 2026-10-08 close $36.18
- P/En/a negative earnings
- Net margin-7.0% FY2025, SEC XBRL
- Gross margin+74.3% FY2025, SEC XBRL
- ROE-12.2% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)+23.6% as of 2026-09-03
- Revenue CAGR (3y)+17.6% SEC XBRL
- Beta0.68 as of 2026-09-03
- Last reported earnings2026-07-29 SEC EDGAR Form 8-K (Item 2.02)
How AXGN compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross margintop 25% 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
AXGN is not currently in any published Top 10 list. Its scores are below.
Top 10 score
42.4 #1117 of 1,389 scored · #127 of 151 in Health Care
Growth 80th (revenue growth year over year 23.6%, 3-year revenue CAGR 17.6%) and trend 58th (over the past 12 months this stock beat the market by 94.1 percentage points); weakest is profitability (11th, return on equity -12.2%, operating margin -3.5%).
Scores as of 2 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4. AXGN was not in the scored universe at the latest run on 8 Oct 2026, so these scores are its last ones.
How AXOGEN INC looks technically
AXOGEN INC (AXGN) is trading 7.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 256 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 26, in oversold territory (below 30). It made a new 20-day low about 2 trading days ago. It is 31.6% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 7.0% below its 200-day average, the long-term trend line — a long-term downtrend | -7.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $45.41 | $45.41 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $38.88 | $38.88 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 47. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 256 trading days ago — a "golden cross", a bullish long-term signal | 256 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with sellers in control | 26.4 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 26, in oversold territory (below 30) | 25.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($35.44 to $47.00) — its "stochastic" reading is 6 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 6.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 27 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $52.91 | $52.91 |
|---|---|---|
| From the 52-week high | it is 31.6% below its 52-week high (its highest price of the past year) | -31.6% |
| Above the 52-week low | it is 136.9% above its 52-week low (its lowest price of the past year) | +136.9% |
| Below the 52-week high | it is 31.6% below its highest point of the past year | 31.6% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $56.85 (set on 2018-07-24) | $56.85 |
| Given back of the 52-week move | over the past year its closes ranged ($15.59 to $51.73), and it has given back roughly a third of its rise from last year’s low — 43% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $28.24 to $29.40. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 43.0% |
| From the all-time high | it is 36.4% below its all-time high | -36.4% |
| Nearest price level | it is trading 4.2% above a support level at $34.66 — a price it turned at twice since 2026-01-08, most recently on 2026-04-06. Since 2024-10-08 it has 13 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.2% |
| All-time low | its lowest closing price on record is $0.22 (set on 2006-09-19) | $0.22 |
| Above the all-time low | it is 16345.5% above its all-time low | +16,345% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 89% of the past ~6 months) | 89th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.96 between its high and its low — about 5.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.96 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $35.24 and $48.47 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $35.24 – $41.86 – $48.47 |
| Typical daily range (% of price) | its price moves about 5.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.4% |
| Stretch from the 200-day average | it is trading 1.4 daily ranges below its 200-day average price (7.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.96× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.3% since the prior reading | -1.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|---|---|
| Since a bearish engulfing | 7 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 7 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.2% |
|---|---|---|
| Open gap | it gapped 4.5% below the previous close 20 sessions ago and has not traded back through the level it left behind at 47.27 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -4.5% |
| Gap filled | a 6.9% gap down opened on 2026-07-29 has been "filled" 50 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 50 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 23.6 percentage points (the stock lost 22.5% while the market gained 1.0%) | -23.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 19.2 percentage points (the stock lost 15.4% while the market gained 3.8%) | -19.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 6.6 percentage points (the stock gained 10.8% while the market gained 17.5%) | -6.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 95.9 percentage points (the stock gained 110.8% while the market gained 15.0%) | +95.9% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 21% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.9% of the share price. | -20.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $39.48 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -8.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 18% below the average price paid since it last reported on 2026-07-29 (its 10-Q), so the typical buyer over that stretch is under water. That average is $43.86 — a volume-weighted average of daily closes over 51 sessions, not a true tick-by-tick VWAP. | -17.5% |
Head and shoulders, bearish — broke down · entry $42.87 · 70 sessions in
Price levels it has turned at before
AXGN last closed at $36.18 on 2026-10-08. Since 2024-10-08 it has turned at 13 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $34.66 | Support | 4.2% below the last close | turned there twice · 2026-01-08 to 2026-04-06 |
| $38.20 | Resistance | 5.6% above the last close | turned there three times · 2026-06-02 to 2026-07-29 |
| $34.10 | Support | 5.8% below the last close | turned there three times · 2025-12-04 to 2026-03-16 |
| $39.71 | Resistance | 9.8% above the last close | turned there three times · 2026-04-17 to 2026-09-11 |
| $30.16 | Support | 16.6% below the last close | turned there five times · 2026-01-02 to 2026-04-07 |
| $44.31 | Resistance | 22.5% above the last close | turned there twice · 2026-05-07 to 2026-05-20 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $47.00.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 8 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · Analyst price target recently CUT · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.20 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$53.70 range $48.00 – $58.00; median $54.00
Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AXGN
- Consensus EPS estimate$0.1275 next reporting period, as of 2026-10-06
- Estimate change, 30 days-$0.00679 (-5.1%) from $0.1343, on 2026-09-01, 35-day window
- Readings revised upward25% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Uncertainty regarding sustained adoption of nerve repair algorithms by surgical specialties.","Dependency on consistent reimbursement and insurance coverage for peripheral nerve injury procedures.","Operational risks associated with manufacturing, processing, and maintaining inventory of human tissue-based products."]
What changed in the latest 10-Q
AI-assisted comparison of AXGN's 10-Q filed 2026-07-29 against the prior one filed 2026-04-28.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing adds the quarter ended June 30, 2026 figures: revenues of $69,731, gross profit of $50,674, and net loss of $(1,516) compared to the prior year quarter.
- Newer filing adds a revenue increase detail: revenues increased $13,069 or 23.1% compared to the quarter ended June 30, 2025.
- Newer filing adds a gross profit increase detail: gross profit increased $8,656 or 20.6% compared to the quarter ended June 30, 2025.
- Newer filing adds operational highlights: Publication of REPOSE, a prospective, randomized clinical study evaluating Axoguard Nerve Cap for symptomatic neuroma management.
- Newer filing adds operational highlight: Initiation of Nerve-RESTORE, a prospective, randomized, assessor-blinded study comparing Avance Nerve Graft to sural nerve autograft.
- Newer filing adds operational highlight: Acquired a minority ownership stake in Trace Biosciences, including a limited right of first refusal.
- Newer filing describes year-to-date revenue growth through the second quarter of 2026 as broad-based across all markets, driven by 20% plus year-over-year account productivity, expanding sales force coverage, and improving commercial insurance coverage and payment.
- Newer filing adds a results of operations table for the three months ended June 30, 2026 and 2025, including cost of goods sold, operating expenses, other income (expense), and net loss figures for that period.
- Removed:
- Older filing's quarterly highlights for the quarter ended March 31, 2026 (revenues of $61,457, gross profit of $46,189) are no longer presented in the newer filing since it reports the next quarter.
- Older filing removed highlight: Received positive coverage decisions from Cigna and Elevance Health, two of the nation's largest commercial insurers.
- Older filing removed highlight: Effective January 1, 2026, CMS created a new Level 3 Nerve Procedure Code, increasing Avance facility reimbursement 40% year-over-year to $9 for hospital outpatient and 35% to $6 for ASC-based procedures.
- Older filing removed highlight: On January 23, 2026, Axogen closed an upsized public offering with the sale of 4,600,000 shares of common stock, yielding net proceeds of $133,252, with $69,707 used to fully repay and terminate the Credit Facility on January 28, 2026.
- Older filing's results of operations table and discussion for the three months ended March 31, 2026 and 2025 are removed, including revenue, gross profit, loss from operations, loss on extinguishment of debt, and net loss figures for that period.
- Reworded:
- Newer filing changes the comparison period heading from 'Comparison of the Three Months Ended March 31, 2026 and 2025' to 'Comparison of the Three Months Ended June 30, 2026 and 2025'.
- Newer filing changes the mention of the BLA from 'the FBA approved the BLA for Avance' to 'the FDA approved the Biologics License Application for Avance'.
- Newer filing changes revenue discussion from the March 31 quarter comparison to the June 30 quarter comparison, with updated dollar amounts and percentage change.
- Newer filing adds a discussion of gross profit change for the June 30 quarter, whereas the older filing had a gross profit discussion for the March 31 quarter.
- Notes:
- Newer filing MD&A text is truncated after the sentence beginning 'The increase in revenues was primarily driven by an increase in unit volume and' so later portions of that section are not included in the provided text; comparison is limited to the text actually provided.
- The additional sections after the revenues discussion in each filing (e.g., gross profit, operating expenses, liquidity) are not fully shown for the newer filing, limiting completeness of the comparison.
Risk Factors
- Added:
- In the filing dated 2026-07-29, the Rule 10b5-1 Trading Plans table adds an adoption entry for Kathy Weiler, Director, adopted 5/8/2026, with 35,976 aggregate securities to be sold and expiration date 1/31/2027.
- In the filing dated 2026-07-29, the Rule 10b5-1 Trading Plans table adds an adoption entry for Amy Wendell, Director, adopted 5/12/2026, with 13,353 aggregate securities to be sold and expiration date 6/1/2027.
- In the filing dated 2026-07-29, the Rule 10b5-1 Trading Plans table adds an adoption entry for Joseph A. Tyndall, Director, adopted 6/3/2026, with 3,500 aggregate securities to be sold and expiration date 6/3/2027.
- Removed:
- In the filing dated 2026-04-28, the Rule 10b5-1 Trading Plans table includes an adoption entry for Marc Began, Executive Vice President, General Counsel and Chief Compliance Officer, adopted 3/11/2026, with 67,500 aggregate securities to be sold and expiration date 12/31/2026, which is not present in the filing dated 2026-07-29.
- Reworded:
- In the filing dated 2026-07-29, the introductory sentence to the Rule 10b5-1 Trading Plans disclosure refers to 'the three months ended June 30, 2026'; in the filing dated 2026-04-28, the same sentence refers to 'the three months ended March 31, 2026'.
- Notes:
- The section labeled 'Risk Factors' in both filings consists only of a statement that there have been no material changes to the risk factors disclosed in the 2025 Annual Report on Form 10-K; because no actual risk factor text is reproduced, no comparison of substantive risk factor language is possible.
- The texts include subsequent items (Items 2 through 6 and signatures) that are outside the 'Risk Factors' section; changes in those items (including trading plan entries and exhibit details) were included for completeness but fall outside the named Risk Factors section proper.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 4 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 4 sells ($5M) — 4 selling insiders
- Last 180 days · read to 2026-10-040 buys · 11 sells ($6M) — 8 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-02. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AXGN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding AXGN as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 9,644,555
- Reported value $445,481,979
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about AXGN's institutional holders → See what each manager we track holds →
Short interest (FINRA)
AXGN had 4,055,417 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
AXGN had 7.54% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.86 days to cover at the same settlement.
- Reported short interest (shares) 4,055,417
- Short interest (% of shares outstanding) 7.54%
- Prior settlement (shares) 3,809,350
- Reported change 6.46%
- Days to cover (reported) 2.86
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AXGN vs…
AXOGEN INC is found in…
Frequently asked questions
What does AXOGEN INC (AXGN) do?
Axogen is a medical technology company focused on the development and commercialization of innovative surgical solutions for peripheral nerve repair. Its portfolio includes processed nerve allografts, nerve conduits, and nerve wrap products used to address nerve damage. The company provides a comprehensive surgical solution to restore nerve function and improve quality of life for patients.
What sector is AXOGEN INC (AXGN) in?
AXOGEN INC (AXGN) is classified in the Health Care sector. Its industry is medical devices / surgical instruments. It trades on NASDAQ.
Who are AXOGEN INC's (AXGN) competitors?
Notable peers of AXOGEN INC (AXGN) include Integra LifeSciences, Stryker, Medtronic and Johnson & Johnson. This peer set is informational only — not financial advice.
Is AXOGEN INC (AXGN) overbought or oversold right now?
AXOGEN INC (AXGN) is currently in oversold territory (its 14-day RSI is 26, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AXGN come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.